TNFRSF9 and neoplasm: Regarding the use of anti-CD137 MoAb in a clinical setting has raised particular interest, since it appeared capable of having a beneficial effect on tumor regression and oncological patient response, both when used as single agent and even more when combined to other drugs or anticancer treatments [44,54,55,65,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132].